Table 4.
Vaccine Efficacy/Effectiveness Against Variants Possessing E484K
| Vaccine | Number of Participants | Country | Period | Vaccine Efficacy/ Effectiveness | Ref. |
|---|---|---|---|---|---|
| BNT162b2 | 265,410 | Qatar | December 21, 2020–March 31, 2021 | Vaccine efficacy against any documented infection -Alpha variant: 89.5% (95% CI, 85.9 to 92.3) -Beta variant: 75.0% (95% CI, 70.5 to 78.9) |
[33] |
| ChAdOx1 nCoV-19/AZD1222 | 2026 | South Africa | June 24–November 9, 2020 | -Vaccine efficacy for preventing mild-to-moderate infection: 21.9% (95% CI, −49.9 to 59.8) -Vaccine efficacy for beta variant infection: 10.4% |
[25] |
| Ad26.COV2.S | 43,783 | USA and South Africa | September 21, 2020-January 22, 2021 | Overall vaccine efficacy: -74% in the United States -52% in South Africa (Beta variant accounts for 95% of the Covid-19 infection in South Africa) |
[34] |
| NVX-CoV2373 | 29,960 | USA and Mexico | January 25- April 30, 2021 | -Mostly Alpha variant -Vaccine efficacy: 90.4% (95% CI 82.9–94.6) for preventing mild, moderate, or severe infection |
[59] |
| 4387 | South Africa | August 17, 2020-November 25, 2020 | -Mostly Beta variant -Vaccine efficacy: 49.4% (95% CI 6.1–72.8) for preventing mild-to-moderate Covid-19 |
[36] |